论文部分内容阅读
骨髓移植治疗白血病是一种有效的治疗措施,异基因骨髓移植(ALLO—BMT)存在供髓来源困难,又受年龄限制。自体骨髓移植(ABMT)不存在髓源困难,基本上不受年龄限制,但复发率较高。为减少ABMT后白血病复发,目前有许多学者正在探索企图净化残留在骨髓中的白血病细胞后进行ABMT。此种骨髓净化后的ABMT,在我国独生子女日益增多的情况下,应成为我们研究的一个重要课题。体外净化骨髓中残留的白血病细胞,免疫学方法特异性最强,是一种较理想的方法。1988年5月～1989年7月,我们对4例普通型急性淋巴细胞白血病(CALL)患者缓解后,采用单克隆抗体55(McAb55)在体外净化骨髓中残
Bone marrow transplantation for the treatment of leukemia is an effective treatment, allogeneic bone marrow transplantation (ALLO-BMT) for the availability of sources of marrow, but also by the age limit. Autologous bone marrow transplantation (ABMT) does not present with myeloid problems and is virtually age-independent but has a high recurrence rate. To reduce the recurrence of leukemia after ABMT, many scholars are currently exploring ABMT in an attempt to purify leukemic cells remaining in the bone marrow. This kind of bone marrow purified ABMT, in our country’s one-child situation is increasing day by day, should become our research an important subject. In vitro purification of bone marrow residual leukemia cells, the strongest immunological methods, is a more ideal method. From May 1988 to July 1989, we used monoclonal antibody 55 (McAb55) to purify bone marrow in vitro after remission of 4 patients with common acute lymphoblastic leukemia (CALL)